1. O-027Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. (2nd July 2019) Authors: Finn, R S; Ryoo, B-Y; Merle, P; Kudo, M; Bouattour, M; Lim, H-Y; Breder, V; Edeline, J; Chao, Y; Ogasawara, S; Yau, T; Garrido, M; Chan, S L; Knox, J; Daniele, B; Ebbinghaus, S W; Chen, E; Siegel, A B; Zhu, A X; Cheng, A-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. (23rd October 2018) Authors: Pujol, J-L; Greillier, L; Audigier Valette, C; Moro-Sibilot, D; Uwer, L; Hureaux, J; Thiberville, L; Carmier, D; Madelaine, J; Otto, J; Gounant, V; Merle, P; Mourlanette, P; Molinier, O; Renault, P A; Mazieres, J; Antoine, M; Langlais, A; Morin, F; Souquet, P-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 152OEfficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. (25th November 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J-F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PD-002A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis. (20th June 2018) Authors: Chajon, E; Pracht, M; De Baere, T; Nguyen, F; Bronowicki, J; Vendrely, V; Baumann, A; Croisé-Laurent, V; Rio, E; Rolland, Y; Le Sourd, S; Gustin, P; Perret, C; Mornex, F; Peiffert, D; Merle, P; Deutsch, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PD-002A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis. (20th June 2018) Authors: Chajon, E; Pracht, M; De Baere, T; Nguyen, F; Bronowicki, J; Vendrely, V; Baumann, A; Croisé-Laurent, V; Rio, E; Rolland, Y; Le Sourd, S; Gustin, P; Perret, C; Mornex, F; Peiffert, D; Merle, P; Deutsch, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O-011Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). (20th June 2018) Authors: Merle, P; Rimassa, L; Ryoo, B; Cicin, I; Harris, W; Banu, E; Sarker, D; Tan, B; Van Vlierberghe, H; Sen, S; Love, C; Cheng, A; Meyer, T; Kelley, R; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 100PComparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC. (23rd October 2018) Authors: Garcia, J; Delherme, A; Geigeur, F; Merle, P; Tissot, C; Jones, F S; Edelstein, D; Souquet, P-J; Rodriguez-Lafrasse, C; Couraud, S; Payen, L F; Xu, Z Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 711PHepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy. (23rd October 2018) Authors: Pracht, M; Chajon, E; de Baere, T; Nguyen, F; Bronowicki, J-P; Vendrely, V; Baumann, A-S; Croisé-Laurent, V; Rio, E; Rolland, Y; Le Sourd, S; Gustin, P; Perret, C; Mornex, F; Peiffert, D; Merle, P; Deutsch, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 702POutcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Kelley, R K; El-Khoueiry, A B; Meyer, T; Rimassa, L; Merle, P; Chan, S L; Tran, A; Parnis, F; Tam, V C; Cattan, S; Markby, D W; Clary, D O; Cheng, A-L; Abou-Alfa, G K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 123PGene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC). (23rd October 2018) Authors: Radosevic-Robin, N; Ong, S; Warren, S E; Kossai, M; Godfraind, C; Masson, M; Janicot, H; Merle, P; Dubray-Longueras, P; Durando, X; Morel, P; Cesano, A; Penault-Llorca, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗